Bicycle Therapeutics is developing a new class of medicines to treat cancer and other debilitating diseases. Bicycle Drug Conjugates are designed to rapidly and selectively penetrate the tumour, delivering toxins directly to where they are needed while minimising exposure to normal tissue and associated toxicities.
Bicyclic peptides (Bicycles®) are a new therapeutic modality combining the attributes of antibodies, small molecules and peptides within one molecule. Bicycles® exhibit the affinity and exquisite target specificity associated with antibodies. Their small size enables rapid and deep tissue penetration, allowing tissues and tumours to be targeted from within. Their peptidic nature provides a “tuneable” pharmacokinetic half-life and a renal route of clearance, thus avoiding the liver and gastrointestinal tract toxicity often seen with other drug modalities.
Bicycles® can be used as stand-alone therapeutic entities or coupled to deliver a variety of therapeutic payloads; Bicycle Therapeutics’ initial focus is on Bicycle Drug Conjugates® (BDCs) that selectively deliver toxins to tumours. BDCs take advantage of Bicycles®’ inherent properties of high target specificity, fast penetration into the tumour and low systemic exposure, combined with rapid excretion of excess toxin via the kidney.
The company is collaborating in oncology and in other areas to realise the full therapeutic potential of the Bicycle® technology.
Bicycle Therapeutics is well-positioned to exploit the promise of its bicyclic peptide technology platform and is supported by top-tier investors. The company is developing its own pipeline of bicycle molecules as well as seeking research collaborations, providing a variety of opportunities for candidates seeking to join a dynamic and entrepreneurial biotech company.